Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.
December 2017—Aushon BioSystems and ABL announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. ABL will offer this proprietary technology as a new addition to its service offerings in support of pharmaceutical and clinical research clients.
December 2017—Binding Site’s Immunologicals Group offers a comprehensive line of disease state sera in its portfolio of products available to in vitro diagnostic manufacturers and clinical research facilities. The line of products follows all current regulatory and quality standards guidelines and provides materials from a variety of disease state conditions, including ANAs, ANCAs, aPLs, ENAs, infectious and contagious diseases, inflammation markers, and autoantibodies focused on a variety of human organs and tissues.
December 2017—DiaSorin Molecular introduced group C and group G Streptococcus primer pairs and a Pneumocystis jirovecii primer pair for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers.
December 2017—Promega Corp.’s bioluminescent HiBiT Protein Tagging System can be combined with CRISPR/Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions, as demonstrated in a study published in ACS Chemical Biology (Schwinn MK, et al. Epub ahead of print Sept. 21, 2017. doi:10.1021/acschembio.7b00549).
December 2017—Abacus Diagnostica received the CE mark for the GenomEra Norovirus, a molecular in vitro diagnostic test for the detection and differentiation of norovirus genogroups I and II. The test runs on the GenomEra CDX platform.
December 2017—LabCorp and Cancer Genetics have signed agreements with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. Each laboratory will participate in oncology-focused clinical trials in collaboration with pharmaceutical companies and Thermo Fisher.
December 2017—ArcherDx has earned ISO 13485:2003 and EN ISO 13485:2012 certification from the British Standards Institution. This ISO certification indicates that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic assays.
December 2017—Quidel received 510(k) clearance from the FDA to market its Sofia Lyme FIA for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens from patients suspected of B. burgdorferi infection. The test is intended for use with the Sofia analyzer to aid in the diagnosis of Lyme disease.
December 2017—Hologic has received FDA 510(k) clearance for its Panther Fusion Paraflu assay, a multiplexed assay that runs on the Panther Fusion system.
